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Primary Care Multi-Ethnic Network (PRIME Net)
Informed Consent Cover Letter for Anonymous Surveys
Hepatitis C Clinician Survey
Robert Leverence, MD from RIOS Net and the Department of Internal Medicine of the
University of New Mexico in collaboration with CaReNet and the Southeast Regional
Clinicians Network is conducting a research study. The purpose is to seek a better
understanding of primary care clinicians’ views and management of Hepatitis C.
You are being asked to participate in this study because of your membership in one
of the affiliate networks of PRIME Net (RIOS Net, CaReNet, and the Southeast
Regional Clinicians Network) or you are a member of the University of New Mexico
Preceptorship Network. Approval for this project has been granted from each of the
institutional review boards from the three participating networks.
The survey should take less than 10 minutes to complete. Your involvement in the
study is voluntary, and you may choose not to participate. You may refuse to answer
any of the questions. There are no known risks in this study. There are no names or
identifying information associated with this survey. All data will be kept private
with only the RIOS Net research team having access to it. Data will be reported as
group or subgroup data.
If you have any questions about this research project, please feel free to contact
Shirley Alexander at (505)-272-3489 or salexander@salud.unm.edu. If you have
questions regarding your legal rights as a research subject, may call the UNMHSC
Human Research Review Committee at (505) 272-1129.
Your participation in this survey represents your informed consent.
Simply complete the survey and mail it back in the envelope provided, or mail your
completed survey to this address:
PRIME-Net Hep C Survey
Attn: Sonia
Family Practice Center, 3rd Floor
MSC 095040
1 University of New Mexico
Albuquerque, NM 87131
You can also fax the survey to: (505) 272-4701. Questions or problems with the
paper survey? Please contact: primenet@salud.unm.edu.
Thank you for your time and consideration.
Sincerely,
Shirley Alexander
Sr. Program Manager, RIOS Net
Family & Community Medicine
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Hepatitis C Clinician Survey
Clinicians have limited patient contact in the office due to many competing
demands. Hepatitis C screening, diagnosis, and treatment are often variably
explored and current medical recommendations are not consistent. We would like to
know your views about screening and management of Hepatitis C. Please be candid
with your responses.
This questionnaire should take approximately 10 - 15 minutes to complete for which
you will earn 0.5 hours of CME credit.

1. Compared to the common medical problems you face in practice, how important would
you consider Hepatitis C to be?
More Important

Important

Somewhat Less Important

Much Less Important

2. Compared to the common medical problems you screen for in practice, how important
would you consider screening for Hepatitis C to be?

More Important

Important

Somewhat Less Important

Much Less Important

3. Common risk factors that increase the likelihood of Hepatitis C infection include
intravenous drug abuse and blood transfusion/organ transplant before July 1992.
How do you assess patients for these concerns even if not for the explicit
intention of screening for Hepatitis C. (Check all that apply)

A.

intravenous drug abuse

I do not routinely assess for this risk factor.
I ask patients who give a history of other illicit drug use.
I ask patients who have HIV.
I ask patients who have abnormal liver function tests.
I routinely ask new patients
Other:

_______________________________

If you routinely ask new patients, do you use either a prompt or intake form?

Yes
No
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3.B. Blood transfusion or solid organ transplant before July 1992.

I do not routinely assess for this risk factor.
I ask patients who have abnormal liver function tests.
I ask patients who give a history of hepatitis.
I ask all new patients.
Other: _______________________________________

4. Abnormal ALT levels may also indicate infection with Hepatitis C. Under what
circumstances do you order serum ALT levels? (Check all that apply)

I do not routinely order serum ALT levels.
I order an ALT when patients have other risk factors for hepatitis.
I order an ALT when patients give a history of hepatitis.
I order an ALT as routine screening for new patients.
I order an ALT for periodic screening of established patients.
Other:________________________________________

5. In clinical situations where one of the three concerns addressed above is
present, how often do you screen for Hepatitis C by ordering a Hepatitis C
antibody?

A. Patients with a history of intravenous drug abuse.

Always

Frequently

Sometimes

Infrequently

Never

Not Applicable

B. Blood transfusion or solid organ transplant before July 1992.

Always

Frequently

Sometimes

Infrequently
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5.C. Patients with abnormal serum ALT level (obtained either by screening or by
review of previously ordered labs).

Always

Frequently

Sometimes

Infrequently

Never

Not Applicable

6. Please indicate whether each of the following factors influence your approach to
the assessment and screening for Hepatitis C risk factors:
Yes

No

N/A

A. Guideline recommendations
B. The high prevelance of Hepatitis C among my
patients
C. The low prevelance of Hepatitis C among my
patients
D. Treatment effectiveness (in regard to
inducing long term remissions or in regard to
better clinical outcomes.)
E. Treatment ineffectiveness (in regard to
inducing long term remissions or in regard to
better clinical outcomes.)
F. The consequences of untreated hepatitis C
can be serious for some people
G. The consequences of untreated hepatitis C
are not serious for most people
H. Treatment availability
I. Treatment tolerance
J. Financial barriers
K. Too many other competing issues to deal
with in the limited time available in the
encounter
L. The presence of important co-morbidities in
patients(e.g. alcohol use, mental health issues
such as depression)
M. Other:

7. How confident are you in your knowledge of confirmatory/diagnostic tests (i.e.
Hepatitis C RIBA and Hepatitis C PCR) now being used in the assessment of patients
who are Hepatitis C antibody positive?
Very Confident

Somewhat Confident
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8. How confident are you in your knowledge of current anti-viral therapy for
Hepatitis C (e.g. choice of drug, potential side effects)?
Very Confident

Somewhat Confident

Not Confident at all

9. Please indicate the extent to which you agree or disagree about whether primary
care providers should be doing the following with respect to Hepatitis C.

A. Screening
Strongly Agree

Agree

Unsure

Disagree

Strongly Disagree

Agree

Unsure

Disagree

Strongly Disagree

B. Diagnosis
Strongly Agree

C. Treatment with anti-viral therapay:
Strongly Agree

Agree

Unsure

Disagree

Strongly Disagree

Disagree

Strongly Disagree

D. Monitoring and follow-up:
Strongly Agree

Agree

Unsure

E. Referral for consultation and co-management of Hepatitis C:
Strongly Agree

Agree

Unsure
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9.F. Referral for all Hepatitis C management:
Strongly Agree

Agree

Unsure

Disagree

Strongly Disagree

10.
To your knowledge, the number of patients in your practice who are Hepatitis C
positive, and for whom you consider yourself their primary care provider, is
approximately:
none (Check box and go to Q. 24)
1 - 5
6 - 10
11 - 20
More than 20

11.
During the past year how many new diagnoses of hepatitis C have you made?
(A new case is any case in which the patient did not know they had Hepatitis C
until you tested them.)

None
1 - 5
6 - 15
More than 15

12. Which of the following do you routinely offer to patients with Hepatitis C?
(Please check all that apply)

Counseling about alcohol avoidance
Counseling about acetaminophen avoidance
Hepatitis A vaccination/testing
Hepatitis B vaccination/testing
HIV testing
VDRL/RPR testing
Other: ______________________________________________
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13. Approximately what percent of patients in your practice with Hepatitis C
have you referred for treatment?
Less than 25 %
25 - 75 %
More than 75 %
What is the primary reason(s) for your referral rate?

14. Have you ever prescribed anti-viral therapy for Hepatitis C?

No (Check box and go to Q.17)
Yes

15. What types of anti-viral therapy have you given? Check all that apply.

Interferon
Pegylated Interferon
Ribaviran
Other: _______________________________________________________

16. How many patients have you personally treated in the past year for
Hepatitis C? (By “treatment” we mean you have prescribed treatment.)
None
1 - 5
6 - 10
Greater than 10

If greater than 10, please tell us how many:
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17. For those patients who you have referred for treatment, who did you refer them
to? (Check all that apply) (If None, then fill circle & go to Q.23)
None of my patients have undergone treatment or referral for treatment
A local primary care colleague.
A distant primary care colleague.
A local non-university specialist.
A distant non-university specialist.
A local university consultant.
A distant university consultant.
Other: _______________________

18. For those patients who you have referred for treatment, please estimate what
percent were able to complete their full course of treatment:

Less than 25%
25 - 75%
Greater than 75%
Don't Know

19. How satisfied are you with the current availability of Hepatitis C treatment
services for your patients?

Very Satisfied

Somewhat Satisfied

Somewhat Unsatisfied

Very Unsatisfied

What is the primary reason(s) for your satisfaction/dissatisfaction?

20. How satisfied are you with the current quality of treatment services for
Hepatitis C?
Very Satisfied

Somewhat Satisfied

Somewhat Unsatisfied

Very Unsatisfied

What is the primary reason(s) for your satisfaction/dissatisfaction?
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21. For your patients with Hepatitis C who you have treated or who you have
referred for treatment:

A. How many had trouble tolerating treatments?
All

Most

Few

None

Don't Know or Not Applicable

B. How many had trouble complying with treatments?

All

Most

Few

None

Don't Know or Not Applicable

C. How many had trouble with transportation issues related to treatment?

All

Most

Few

None

Don't Know or Not Applicable

D. Other problems related to getting treatment?
__________________________________________________________________________________

22. For your patients who started treatment yet stopped it prematurely, what do you
believe are the primary reasons treatment was stopped? (Please rank)

Not applicable. None of my patients have stoppped treatment prematurely. Go to Q.23

Poor tolerance of treatment
Poor access to treatment services or staff
Financial problems
Poor compliance
Other: _______________________
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23. For your patients who have not undergone treatment for Hepatitis C, what do you
believe are the primary reasons? (Please rank)

Not applicable. All my patients have undergone treatment, fill circle and go to Q.24
Alcohol use, psychiatric morbidity, or other contra-indication
Poor access to treatment services or staff
Insurance companies will not cover treatment
Lack of insurance
Lack of patient interest in treatment
Poor tolerance of treatment (recently or in the past)
My personal views of treatment
Other:___________________________________

24. Would you be interested in attending a telemedicine conference series or other
distant learning opportunity in order to develop specific proficiency for
treatment of Hepatitis C?

(If you are interested or want
more information, please contact:
rleverence@salud.unm.edu)

Yes
Maybe
No

25. Do you have any other thoughts on current or future approaches to the
identification, evaluation and management of patients with Hepatitis C?
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Are you a resident in training?
Yes
No
How many years ago did you complete your primary care residency?
Not applicable.
Less than 5
5 - 10
10 - 20
More than 20
Which statement best describes your clinical practice?
Community Health Clinic
Indian Health Service
University faculty
Veterans Administration
Solo practioneer
Other group pratice
What is your specialty?
Family Practice
Pediatrics
Internal Medicine
Nurse practioner / Physician Assistant
Please select the category that best describes the community in which your primary
practice is located: (Your primary practice is the location at which you spend the
greatest percentage of your time seeing patients.)
Town <= 25,000 people
Town > 25,000 but < 100,000 people
City of 100,000 to 500,000 people
Urban or suburban area in city of > 500,000 people (not inner city)
Inner city of area of metropolis > 500,000 people

Thank you for taking the time to complete this survey. Your input will help the
PRIME-Net research networks understand the problems of treating Hepatitis C.
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PLEASE PLACE YOUR CME ASSESSMENT IN THE ENVELOPE PROVIDED
TO ASSURE THAT YOUR RESPONSES REMAIN ANONYMOUS.
In order to earn your CME credit, please complete the following assessment. Your
Hepatitis C Clinician Survey responses will be anonymously processed and will not
be linked to your responses to this CME assessment in any way.

1. Did this questionnaire meet its objective of gathering information on your
attitudes, knowledge, and practices with regard to Hepatitis C?
Comments
Yes
No

2. Do you feel the questionnaire was clearly written, avoiding confusing
instructions, terms or jargon?
Comments
Yes
No

3.Do you feel any important questions about Hepatitis C were missing from the
questionnaire?
Comments
Yes
No

4. Do you feel the questionnaire was biased in any manner?
Yes

No

Comments

First Name
Last Name
PIN (please enter the last 4 digits of your SSN)
Address
City, State and Zip
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Thank You
We appreciate your participation in PRIME-Net's Hepatitis C Clinician Survey and
CME. For further information, please visit: http://hsc.unm.edu/som/primenet/
or contact: primenet@salud.unm.edu

Further Educational Activities on Hepatitis C
If you are interested in more information about this topic, you can particiapte in
the following activities:
Hepatitis C, Primary Care Providers, and Telemedicine: An Education Model for
Treatment and Management of Hepatitis C Patients: Project ECHO (0.5 CME credits)
has a primary care Hepatitis C Treatment CME Survey. Sponsored by the University of
New Mexico Health Science Center.
http://hsc.unm.edu/som/surveys/echo/index.shtml
NIH Consensus Development Program (1 CME credit) provides a comprehensive review of
current management issues related to Hepatitis C.
http://consensus.nih.gov/2002/2002HepatitisC2002116html.htm
Hepatitis C Support Project (up to 2 CME credits )is a non-profit organization
established to educate, and provide service and support to communities and medical
providers. Hepatitis C CME activities are available through this site.
http://www.hcvadvocate.org/
Hepatitis C: What Clinicians and Other Health Professionals Need to Know is a CDC
web-based module ( a Fact Sheet and a FAQ page with multiple links) designed to
educate health professionals on the epidemiology, prevention, diagnosis, and
treatment of Hepatitis C. CME credit assignment is temporarily unavailable.
http://www.cdc.gov/ncidod/diseases/hepatitis/c/fact.htm

